SENTI-202

SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies

What's the purpose of the trial?

This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.

Trial status

Accepting patients

Phase

Phase 1

Enrollment

Last Updated

1 month ago

Am I Eligible

Participating Centers

There are 6 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

SENTI-202 is a kind of off-the-shelf immunotherapy that may work by modifiying natural killer cells using chimeric antigen receptors (CAR) to recognize and attack the CD33 and/or FLT3 antigen found on different kinds of cancer cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

SENTI-202 CAR NK cell therapy

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.